Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Uzatresgene autoleucel - US WorldMeds

Next Previous
Drug Profile

Uzatresgene autoleucel - US WorldMeds

Alternative Names: ADP-5701; ADP‑A2M4CD8; Autologous genetically modified ADP-A2M4CD8 cells; Melanoma-associated antigen A4-specific T-cells co-expressing CD8 alpha - Adaptimmune; uza-cel

Latest Information Update: 10 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Adaptimmune
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastric cancer; Oesophageal cancer; Ovarian cancer
  • Phase I Solid tumours

Most Recent Events

  • 08 May 2026 Galapagos NV is now called Lakefront Biotherapeutics
  • 11 Nov 2025 Adaptimmune terminates enrollment in the phase-II SURPASS-3 clinical trials in Ovarian cancer (Monotherapy, Combination therapy, In adults, In the elderly, Late-stage disease, Second-line therapy or greater) in the USA, United Kingdom, Spain, France, Canada (IV) (NCT05601752) (Adaptimmune pipeline, November 2025)
  • 11 Nov 2025 Adaptimmune terminates enrollment in the phase-I clinical trials in Solid tumours (In adults, In the elderly) in France, United Kingdom, USA, Belgium, Canada, Spain (IV) prior to November 2025 (NCT04044859) (Adaptimmune pipeline, November 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top